EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE)
Investegate announcements from Excision BioTherapeutics, Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine - read this article along with other careers information, tips and advice on BioSpace
Published: Feb 17, 2021
SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) Excision BioTherapeutics Inc. (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simplex Virus, and EBT-107 for Hepatitis B.
The financing round was led by GreatPoint Ventures with support from existing investor ARTIS Ventures. New investors include Adjuvant Capital, Norwest Venture Partners, Anzu Partners, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, and Olive Tree Capital. Ashok Krishnamurthi, Managing Partner at GreatPoint Ventures, will join the Board of Di